FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer
Fudan University
Fudan University
Takeda
Guerbet
Gruppo Oncologico del Nord-Ovest
Rutgers, The State University of New Jersey
The Affiliated Hospital of Qingdao University
Dharmais National Cancer Center Hospital
University of Colorado, Denver
Affiliated Cancer Hospital of Shantou University Medical College
Fudan University
University Hospital of Split
University Hospital of Split
VA Office of Research and Development
Udayana University
Bayer
Fudan University
Hospital Civil de Guadalajara
Nova Scotia Health Authority
Zhongnan Hospital
Sir Run Run Shaw Hospital
The Institute of Molecular and Translational Medicine, Czech Republic
The Institute of Molecular and Translational Medicine, Czech Republic
The First Affiliated Hospital of Nanchang University
Tanta University
Ciusss de L'Est de l'Île de Montréal
Rush University Medical Center
Myriad Genetic Laboratories, Inc.
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
McGill University Health Centre/Research Institute of the McGill University Health Centre
Helsinki University Central Hospital
Hospital Clinic of Barcelona
Yonsei University
Cedars-Sinai Medical Center
Kaohsiung Medical University Chung-Ho Memorial Hospital
Fudan University
Dr. Reddy's Laboratories Limited
Asan Medical Center
Hoffmann-La Roche
VA Office of Research and Development
Amsterdam UMC, location VUmc
University Hospital, Limoges
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Erasmus Medical Center
Newcastle-upon-Tyne Hospitals NHS Trust
Grupo Espanol Multidisciplinario del Cancer Digestivo
Hoffmann-La Roche
Fudan University
China Meitan General Hospital
Boston Scientific Corporation
Kaunas University of Medicine